Literature DB >> 15661057

Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.

Hideki Ouchi1, Hitoshi Ishiguro, Naoya Ikeda, Mayumi Hori, Yoshinobu Kubota, Hiroji Uemura.   

Abstract

AIM: To clarify the mechanism of the anticancer effect of genistein, we examined the effect of genistein on telomerase activity in prostate cancer cells. We hypothesized that genistein may exert its anticancer effect by modifying telomerase activity in prostate cancer cells.
METHODS: Prostate cancer (LNCaP) cells were cultured with genistein and the number of viable cells was counted. Growth medium was also collected to measure prostate-specific antigen (PSA) concentration. Polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay and reverse transcriptase (RT)-PCR analysis were performed to investigate telomerase activity and the expression of human telomerase reverse transcriptase (hTERT), c-myc and p21 mRNA. To examine the possibility that hTERT transcriptional activity is modulated by genistein, transient cell transfection studies were performed by using luciferase reporter assay. Telomere repeat amplification protocol (TRAP) assay and PCR analysis of hTERT were performed in androgen independent cells, DU-145.
RESULTS: Cell growth of LNCaP was inhibited by genistein and PSA secretion was similarly reduced. In TRAP assay, the telomerase activity of LNCaP cells was reduced by genistein. Reverse transcriptase-PCR analysis revealed that the expression of hTERT and c-myc mRNA was down-regulated by genistein, whereas p21 mRNA increased in response to genistein. Luciferase reporter assay revealed that genistein reduced the transcriptional activity of hTERT. In DU-145 cells, telomerase activity and the expression of hTERT mRNA were also reduced by genistein.
CONCLUSION: The current study elucidated the molecular mechanism of cell growth inhibition by genistein. The antiproliferative effects of genistein seem to be exerted on the hTERT transcriptional activity via different molecular pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661057     DOI: 10.1111/j.1442-2042.2004.00973.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  26 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.

Authors:  Yingming Li; Bahaa S Malaeb; Zhong-Ze Li; Melissa G Thompson; Zhi Chen; David R Corey; Jer-Tsong Hsieh; Jerry W Shay; Kenneth S Koeneman
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

3.  Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents.

Authors:  Pahoua Xiong; Rubing Wang; Xiaojie Zhang; Eduardo DeLa Torre; Francisco Leon; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

Review 4.  Epigenetic linkage of aging, cancer and nutrition.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

5.  Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Shanjayla Connors; Ganna Chornukur; Shohreh Iravani Dickinson; Wenlong Bai; Christopher R Williams; Raoul Salup; Wui Fu
Journal:  J Cancer Sci Ther       Date:  2012-01-10

Review 6.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

7.  Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

Authors:  Nagi B Kumar; Loveleen Kang; Julio Pow-Sang; Ping Xu; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Jeffrey P Krischer
Journal:  J Soc Integr Oncol       Date:  2010

8.  A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

9.  Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways.

Authors:  Kim M Malloy; Jiandong Wang; Leslie H Clark; Ziwei Fang; Wenchuan Sun; Yajie Yin; Weimin Kong; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

Review 10.  [A critical assessment of phytotherapy for prostate cancer].

Authors:  F G E Perabo; E C von Löw; R Siener; J Ellinger; S C Müller; P J Bastian
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.